Marshall Wace, LLP Intra Cellular Therapies, Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 1,079,757 shares of ITCI stock, worth $139 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
1,079,757
Previous 1,160,973
7.0%
Holding current value
$139 Million
Previous $84.9 Million
6.23%
% of portfolio
0.11%
Previous 0.11%
Shares
16 transactions
Others Institutions Holding ITCI
# of Institutions
416Shares Held
88.5MCall Options Held
284KPut Options Held
105K-
Vanguard Group Inc Valley Forge, PA9.72MShares$1.25 Billion0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$813 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.13MShares$659 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.25MShares$418 Million1.36% of portfolio
-
Norges Bank Oslo, Q83.21MShares$413 Million0.04% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $12.1B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...